PD-L1 Expression in Muscle Invasive Urothelial Carcinomas as Assessed via Immunohistochemistry: Correlations with Specific Clinical and Pathological Features, with Emphasis on Prognosis after Radical Cystectomy
Autor: | Angela Borda, Adela Nechifor-Boilă, Myriam Decaussin-Petrucci, Septimiu Voidazan, Andrada Loghin, Bogdan Călin Chibelean, Ioan Alin Nechifor-Boilă, Orsolya Martha |
---|---|
Rok vydání: | 2021 |
Předmět: |
0301 basic medicine
Oncology medicine.medical_specialty Squamous Differentiation medicine.medical_treatment Science General Biochemistry Genetics and Molecular Biology Article Cystectomy immune checkpoint inhibitors 03 medical and health sciences 0302 clinical medicine Internal medicine medicine Risk factor Lymph node Pathological Ecology Evolution Behavior and Systematics business.industry Paleontology 030104 developmental biology medicine.anatomical_structure lymphatic node status overall survival Space and Planetary Science muscle-invasive bladder cancer 030220 oncology & carcinogenesis Immunohistochemistry T-stage business tumor stage Immunostaining |
Zdroj: | Life Life, Vol 11, Iss 404, p 404 (2021) Volume 11 Issue 5 |
ISSN: | 2075-1729 |
Popis: | In the present study, we analyzed Programmed Death Ligand-1 (PD-L1) expression in radical cystectomy (RC) specimens from patients with muscle-invasive urothelial carcinoma (UC), in order to assess any correlations with specific clinicopathological features and its potential prognostic value. A multi-institutional study was performed within the departments of urology and pathology at the Mureș County Hospital, Romania, and Centre Hospitalier Lyon Sud, France. Sixty-nine patients with MIBC were included, for whom tumor histology (conventional versus histological variant/differentiation), tumor extension (T), lymph node involvement (N), and distant metastases (M) were recorded. PD-L1 immunostaining was performed using the 22C3 clone and was interpreted using the combined positive score (CPS) as recommended (Dako Agilent, Santa Clara, CA, USA). Positive PD-L1 immunostaining was more prevalent among UCs with squamous differentiation compared to conventional UCs and trended towards an improved OS (p = 0.366). We found the T stage to be a risk factor for poor survival in PD-L1-positive patients (HR 2.9, p = 0.021), along with the N stage in PD-L1-negative patients (HR 1.98, p = 0.007). No other clinicopathological factor was found to be significantly associated with PD-L1 positivity. Thus, we confirm the need for PD-L1 immunostaining prior to initiating immune checkpoint inhibitor therapy for a more accurate assessment of the patients’ chances of responding to treatment. |
Databáze: | OpenAIRE |
Externí odkaz: |